Spirulina for liver protection after bile duct cancer surgery
Part of Cancer clinical trials.
This trial tests whether spirulina (a type of algae) can help protect the liver and aid recovery after surgery for bile duct cancer. Participants will take spirulina or a placebo before and after a planned liver resection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with bile duct cancer (cholangiocarcinoma).
- Your liver function should be good enough to be classified as Child-Pugh Class A (a standard measure of liver health).
- You need to be scheduled for a specific treatment plan: chemotherapy (gemcitabine + oxaliplatin), targeted therapy (lenvatinib), and immunotherapy (a PD-1 inhibitor), followed by surgery to remove about half of your liver.
- You must be between 18 and 75 years old and willing to take spirulina or a placebo daily for 3 weeks before and 3 weeks after surgery.
- You cannot have any other active cancer, severe health problems (like uncontrolled heart or lung disease), or a history of liver surgery.
- You must not be allergic to spirulina or have a serious mental health condition that could affect participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy approach after surgery for bile duct or gallbladder cancers. The goal is to see if giving chemotherapy based on a detailed analysis of your tumor (called 3D-PTA) helps prevent the cancer from coming back.
This trial tests whether pembrolizumab combined with gemcitabine and cisplatin given around the time of surgery can improve outcomes for people with high-risk, potentially operable intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help by strengthening the immune system while also treating the cancer with chemotherapy.
This trial tests a combination of chemotherapy and immunotherapy before surgery for locally advanced bile duct cancer. The goal is to see if this approach can shrink the tumor enough to improve surgical outcomes.
This trial combines proton beam therapy with a liver transplant to treat a specific type of bile duct cancer (hilar cholangiocarcinoma). It aims to improve outcomes by using radiation before surgery to help make the transplant more successful.
This trial tests a combination of drugs given before surgery to shrink bile duct cancer and possibly improve outcomes. The drugs include an immunotherapy (tislelizumab) and three chemotherapy agents (gemcitabine, cisplatin, and S-1).
This trial tests whether phycocyanin, a natural supplement, can protect the liver before and after surgery to remove part of the liver. It is for people with a type of bile duct cancer who are already getting chemotherapy and other treatments before surgery.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.